The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

While the National Treasury has released R700m, the Bill and Melinda Gates Foundation and the Wellcome Trust will ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...